Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas and Medivation, Inc., a Pfizer company, Eisai, Inc., Exelixis, Inc., Genomic Health, Inc., Merck & Co., Inc., Prometheus Laboratories, Inc., Sanofi Genzyme, and Seattle Genetics.

Community Practice Connections™: New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

In this online activity, renowned physicians Leonard G. Gomella, MD, Daniel P. Petrylak, MD, and Lawrence H. Schwartz, MD, discuss their perspectives and management approaches for patients with prostate and bladder cancers. The content and interviews are based on presentations delivered in March 2019 at New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. As you work through the activity, you can compare your approach and viewpoints with those of the experts, and review the evidence base underpinning the treatment decisions taken.

As a busy oncologist engaged in the daily management of patients with prostate cancer, clear cell renal cell carcinoma, and urothelial carcinoma, this activity affords a unique opportunity to apply an added layer of information to the ongoing care of your patients.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astellas and Medivation, Inc., a Pfizer company, Eisai, Inc., Exelixis, Inc., Genomic Health, Inc., Merck & Co., Inc., Prometheus Laboratories, Inc., Sanofi Genzyme, and Seattle Genetics.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.

Educational Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Outline the use of patient- and disease-specific characteristics to inform clinical decision-making in the management of patients with GU malignancies
  • Discuss current strategies and practice-changing evidence for the management of patients with GU malignancies across multiple lines of care
  • Explain how to proactively mitigate expected treatment-related toxicities associated with immunotherapeutic and targeted approaches to treat GU cancers
  • Apply emerging clinical trial data for the management of GU malignancies in the context of changing treatment paradigms in the field

Faculty, Staff, and Planners’ Disclosures

Daniel P. Petrylak
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: Agensys, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Dendreon, Endocyte, Genentech, Innocrin, Johnson & Johnson, Lilly, MedImmune, Medivation, Merck, Millennium, Novartis, Pfizer, Progenics, Roche Laborato-ries, Sanofi Aventis, Seattle Genetics, Sotio; Consultant: Amgen, Astellas, AstraZeneca, Bayer, Bellicum, Bristol-Myers Squibb, Clovis, Dendreon, Exelixis, Ferring, Johnson & Johnson, Lilly, Medivation, Millennium, Pfizer, Roche Laboratories, Sanofi Aventis, Seattle Genetics; Shareholder: Bellicum, Tyme

Leonard G. Gomella
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director, Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Philadelphia, PA

Disclosures: Consultant: Astellas, MDxHealth, Janssen, Merck, Pfizer.

Lawrence H. Schwartz
Lawrence H. Schwartz, MD
James Picker Professor and Chairman
Department of Radiology
Columbia University Vagelos College of Physicians and Surgeons
NewYork-Presbyterian Hospital/Columbia
New York, NY

Disclosures: Grant/Research Support: Novartis, Merck; Consultant: Boehringer Ingelheim.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By